Latest Headlines
-
Breakthrough In Indole Chemistry Could Accelerate Drug Development
8/25/2025
A cost-effective copper-catalyzed reaction enables selective modification at the C5 position of the indole ring, a backbone for pharmaceutical compounds
-
Danforth Advisors Acquires PharmaDirections, Expanding Its Integrated Drug Development Services From Discovery Through Commercialization
8/25/2025
Danforth Advisors, LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization.
-
Tivic Receives Two Investigational New Drug Applications For Entolimod For The Treatment Of Acute Radiation Syndrome (ARS) And Advanced Cancers
8/20/2025
Tivic Health Systems, Inc., a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod.
-
Ginkgo Datapoints, Tangible Scientific, And Inductive Bio Partner To Deploy AI-Driven Lab-In-The-loop Workflows Across The Biopharma Industry
8/20/2025
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its Datapoints offering has entered into a new strategic partnership with Inductive Bio and Tangible Scientific to make AI-driven lab-in-the-loop drug discovery broadly accessible across the industry.
-
Elix Provides AI Drug Discovery Platform 'Elix Discovery' To KYORIN Pharmaceutical
8/20/2025
Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”), a Japan-based AI drug discovery company, is pleased to announce that KYORIN Pharmaceutical Co., Ltd. (Headquarters: Tokyo; hereinafter “KYORIN”) has adopted Elix Discovery (https://www.elix-inc.com/platform/), Elix’s proprietary AI-powered drug discovery platform.
-
XtalPi Signs MOU With Dong-A ST For Joint Research And Development Of Immunology And Inflammation Therapies
8/19/2025
XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases.
-
A New Model Predicts How Molecules Will Dissolve In Different Solvents
8/19/2025
Using machine learning, MIT chemical engineers have created a computational model that can predict how well any given molecule will dissolve in an organic solvent — a key step in the synthesis of nearly any pharmaceutical.
-
N-Power Medicine Launches Industry's First Prospective External Control Arm Platform To Dramatically Accelerate Oncology Drug Development And Reduce Reliance On Randomization
8/19/2025
N-Power Medicine, a company reimagining oncology drug development, today announced the launch of the industry’s first Prospective External Control Arm (ProECA) platform for pharmaceutical and biotechnology partners.
-
RemeGen And Santen Enter Into Exclusive Licensing Agreement For Ophthalmic Innovative Drug RC28-E In Greater China And Asian Countries
8/19/2025
RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd. ("Santen").
-
VASTHERA Receives U.S. FDA Clearance To Initiate Phase 1 Clinical Trial Of Pulmonary Arterial Hypertension Drug Candidate, VTB-10
8/19/2025
On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VTB-10, its drug candidate for pulmonary arterial hypertension (PAH), a rare, life-threatening disease marked by elevated blood pressure in the lung arteries.